Get the Stockscreener App
2.04
6.42%
-0.14
Pre-market:
2.06
0.02
+0.98%
Savara Inc stock is traded at $2.04, with a volume of 1.03M.
It is down -6.42% in the last 24 hours and down -33.55% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$2.18
Open:
$2.18
24h Volume:
1.03M
Relative Volume:
0.73
Market Cap:
$402.71M
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-6.1818
EPS:
-0.33
Net Cash Flow:
$-51.36M
1W Performance:
-12.45%
1M Performance:
-33.55%
6M Performance:
-36.65%
1Y Performance:
-47.29%
1-Day Range:
$2.03
$2.19
1-Week Range:
$2.03
$2.3899
52-Week Range:
$1.89
$5.11
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
2.04 | 402.71M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Savara’s SWOT analysis: biotech firm’s stock poised for growth with aPAP drug - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc.SVRA - Eastern Progress
Savara Inc (NASDAQ:SVRA) Stake Reduced by California State Teachers Retirement System - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $482,000 Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ:SVRA) Shares Sold by Bank of America Corp DE - Defense World
Ameriprise Financial Inc. Takes Position in Savara Inc (NASDAQ:SVRA) - Defense World
Jane Street Group LLC Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
savara elects board members and approves proposals at annual meeting - Investing.com Australia
savara elects board members and approves proposals at annual meeting By Investing.com - Investing.com South Africa
Savara Re-elects Board Members at Annual Meeting - TipRanks
Savara Inc (NASDAQ:SVRA) Shares Bought by Squarepoint Ops LLC - Defense World
FDA Requests Additional Data for Savara’s MOLBREEVI Application - MSN
Savara assumed with an Outperform at Oppenheimer - MSN
Nuveen Asset Management LLC Sells 30,766 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc. to Present at Jefferies Global Healthcare Conference on June 4, 2025 - MSN
Millennium Management LLC Grows Stake in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ:SVRA) Shares Bought by ProShare Advisors LLC - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc.SVRA - FinancialContent
Insider Buying Alert: Joseph Mccracken Acquires Additional Shares of Savara Inc (SVRA) - GuruFocus
Oppenheimer assumes Savara stock at outperform, sets $5 price target - Investing.com
Oppenheimer assumes Savara stock at outperform, sets $5 price target By Investing.com - Investing.com Canada
Oppenheimer Adjusts Price Target on Savara to $5 From $15, Maintains Outperform Rating - marketscreener.com
Oppenheimer Maintains Optimism for Savara (SVRA) Despite Filing Setback | SVRA Stock News - GuruFocus
Savara director Joseph McCracken buys $20,825 in stock By Investing.com - Investing.com South Africa
Savara director Joseph McCracken buys $20,825 in stock - Investing.com Australia
What is HC Wainwright’s Forecast for Savara FY2026 Earnings? - Defense World
Savara Inc (NASDAQ:SVRA) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
What is HC Wainwright’s Forecast for Savara FY2029 Earnings? - Defense World
Savara Inc. Grants Equity Awards to New Employees - MSN
FDA Denies Langhorne-Based Savara Application for Rare Lung Disease Treatment - BUCKSCO.Today
Did Savara Inc. (SVRA) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
Savara (NASDAQ:SVRA) Lowered to “Neutral” Rating by HC Wainwright - Defense World
SVRA: Savara Downgraded by HC Wainwright & Co. | SVRA Stock News - GuruFocus
Savara stock rating cut to Neutral by H.C. Wainwright - Investing.com Nigeria
HC Wainwright & Co. Downgrades Savara (SVRA) - MSN
This Starbucks Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
HC Wainwright Downgrades Savara to Neutral From Buy, Adjusts Price Target to $2 From $6 - marketscreener.com
H.C. Wainwright Lowers Savara (SVRA) Outlook Following FDA Setba - GuruFocus
H.C. Wainwright Lowers Savara (SVRA) Outlook Following FDA Setback | SVRA Stock News - GuruFocus
Savara stock price target cut to $2 at Evercore ISI By Investing.com - Investing.com Canada
Savara Inc (NASDAQ:SVRA) Shares Bought by D. E. Shaw & Co. Inc. - Defense World
Guggenheim Reaffirms “Buy” Rating for Savara (NASDAQ:SVRA) - Defense World
Savara (NASDAQ:SVRA) Given New $2.00 Price Target at Evercore ISI - Defense World
Savara (NASDAQ:SVRA) Price Target Lowered to $7.00 at Wells Fargo & Company - Defense World
SVRA ALERT: Levi & Korsinsky Investigates Savara Inc. on Behalf of Shareholders Who Lost Money - ACCESS Newswire
Savara Showcases Promising Phase 3 Trial Data for Molgramostim at ATS 2025 - MSN
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):